This is not the most recent version of the article. View current version (23 DEC 2013)

Intervention Protocol

Daclizumab for relapsing remitting multiple sclerosis

  1. Jia Liu1,*,
  2. Luning Wang1,
  3. Siyan Zhan2,
  4. Jiping Tan1,
  5. Yinyin Xia3

Editorial Group: Cochrane Multiple Sclerosis Group

Published Online: 7 OCT 2009

DOI: 10.1002/14651858.CD008127

How to Cite

Liu J, Wang L, Zhan S, Tan J, Xia Y. Daclizumab for relapsing remitting multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD008127. DOI: 10.1002/14651858.CD008127.

Author Information

  1. 1

    Chinese PLA General Hospital, Department of Geriatric Neurology, Beijing, China

  2. 2

    Peking University Health Science Center, Department of Epidemiology and Biostatistics, School of Public Health, Beijing, China

  3. 3

    School of Public Health, Peking University Health Science Center, Department of Epidemiology and Biostatistics, Beijing, China

*Jia Liu, Department of Geriatric Neurology, Chinese PLA General Hospital, Fuxinglu 28, Beijing, 100853, China. Jason_liu1984@yahoo.cn.

Publication History

  1. Publication Status: New
  2. Published Online: 7 OCT 2009

SEARCH

This is not the most recent version of the article. View current version (23 DEC 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the efficacy and safety of daclizumab for patients with relapsing remitting multiple sclerosis.